NEW YORK – Johnson & Johnson (NYSE: JNJ) has cleared a key threshold of support for its proposed $6.5 billion
1 year ago
Johnson & Johnson (NYSE: JNJ) reported better-than-expected earnings for the second quarter on Thursday and raised its full-year profit outlook.
3 years ago
LAVA Therapeutics N.V. (NASDAQ: LVTX) experienced a significant surge in its stock prices, rising by almost 36.84% after market hours
